Promising prostate cancer drug trial halted early

NCT ID NCT04030559

Terminated Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen May 14, 2026 · Last updated Jun 10, 2026 · Updated 4 times

Summary

This study tested the drug niraparib, given before surgery, in men with high risk prostate cancer that has not spread. The drug targets tumors with specific DNA repair defects. Only 11 participants were enrolled before the trial was stopped, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States

Conditions

Explore the condition pages connected to this study.

ATM GENE MUTATION BRCA1 GENE MUTATION BRCA2 GENE MUTATION BRIP1 GENE MUTATION CDK12 GENE MUTATION CHEK1 GENE MUTATION CHEK2 GENE MUTATION DNA DAMAGE RESPONSE GENE MUTATION DNA REPAIR GENE MUTATION DNA REPAIR GENE MUTATION FANCA GENE MUTATION FANCD2 GENE MUTATION FANCL GENE MUTATION GEN1 GENE MUTATION NBN GENE MUTATION PROSTATE CARCINOMA RAD51 GENE MUTATION RAD51C GENE MUTATION RAD51C GENE MUTATION